

Published in final edited form as:

*Trends Cell Biol.* 2002 February ; 12(2): 72–78.

## Replication Licensing – Defining the Proliferative State?

J. Julian Blow\* and Ben Hodgson

CRC Chromosome Replication Research Group, Wellcome Trust Biocentre, University of Dundee, Dow Street, Dundee DD1 5EH, UK

### Abstract

The proliferation of eukaryotic cells is a highly regulated process that depends on the precise duplication of chromosomal DNA in each cell cycle. Regulation of the replication licensing system, which promotes the assembly of complexes of proteins termed Mcm2-7 onto replication origins, is responsible for preventing re-replication of DNA in a single cell cycle. Recent work has shown how the licensing system is directly controlled by cyclin-dependent kinases (CDKs). Repression of origin licensing is emerging as a ubiquitous route by which proliferative capacity is lowered, and Mcm2-7 proteins show promise as diagnostic markers of early cancer stages. These results have prompted us to propose a functional distinction between the proliferative state and the non-proliferative state (including G0) depending on whether origins are licensed.

### Keywords

Replication licensing; DNA replication; Mcm2-7; cell proliferation; cell cycle; quiescence

If genetic stability is to be maintained, chromosomal DNA must be precisely duplicated in each cell cycle. In order to achieve this, the DNA polymerases and other DNA processing enzymes working at the replication fork must copy the template DNA with high accuracy. It is also crucial that the replication forks are assembled and disassembled correctly to ensure that all the genome is replicated and that no section of it is replicated more than once. This is a particular problem for eukaryotes, whose very large genomes mean that they must use thousands of replication origins (which each initiate a bi-directional pair of replication forks) to duplicate the entire genome in a reasonable period of time. The importance of strict cell cycle regulation of replication origins is outlined in Box 1. Here we review recent developments in our understanding of the replication licensing system which normally prevents replication origins from firing (initiating a bi-directional pair of forks) more than once in each cell cycle<sup>1-5</sup>. These recent results suggest that not only is the licensing system the key to ensuring precise chromosome duplication, but that it also plays an important role in determining the proliferative capacity of cells and has potentially important implications for cancer diagnostics.

### The replication licensing system

How does the cell know whether or not it has already replicated a section of DNA in S phase? What ensures the strict alternation of S phase and mitosis seen in most cells? Recent work has made it clear that the “licensing” of replication origins, achieved by their loading of mini-chromosome-maintenance 2-7 proteins (Mcm2, 3, 4, 5, 6 and 7), provides crucial information to the cell about whether the DNA has been replicated in the current cell cycle<sup>1-5</sup>. The Mcm2-7 polypeptides form a functional hexameric complex<sup>6</sup> that probably

\*j.j.blow@dundee.ac.uk.

comprises an important part of the “pre-Replicative Complex” of replication proteins found at replication origins during G1 phase. On exit from metaphase the replication licensing system becomes activated, so that each origin becomes loaded with Mcm2-7 (Fig 1). The replication licensing system (‘RLS’ in Fig 1) remains active throughout most of G1, but as cells approach S phase, it is inactivated. This means that in S phase, G2 and early mitosis, no further Mcm2-7 can be loaded onto origins. Only licensed origins containing Mcm2-7 can initiate a pair of replication forks, and as initiation occurs at an origin, the bound Mcm2-7 is displaced so that the origin cannot fire again (Fig 1). Mcm2-7 may function as the helicase that unwinds DNA ahead of each replication fork<sup>7</sup>, which would explain their displacement from origin DNA when forks are initiated. As a fail-safe mechanism, it is also envisaged that should an origin be passively replicated by a replication fork emanating from another origin, this would also displace the Mcm2-7 bound to it.

At least three other proteins are required for origins to load Mcm2-7 and become licensed (Fig 1, inset). The Origin Recognition Complex (ORC) first binds to each replication origin, and then recruits two other proteins, Cdc6 (called Cdc18 in *Schizosaccharomyces pombe*) and Cdt1 (also known as RLF-B or *double-parked*)<sup>2-4,8,9</sup>. These proteins in turn load Mcm2-7 complexes and functionally license the origin. A crucial feature is that although ORC, Cdc6 and Cdt1 are all essential for Mcm2-7 loading, none of them are subsequently required to maintain the binding of Mcm2-7 to origins<sup>10-13</sup>. Furthermore it has been shown in *Xenopus* that once origin licensing is complete, ORC and Cdc6 (and probably Cdt1 as well) are no longer required for subsequent DNA replication<sup>11,12</sup>. As discussed below, an important consequence is that re-licensing of replicated DNA can be prevented by inhibition or removal of ORC, Cdc6 or Cdt1 once S phase has started, without displacing functional Mcm2-7 at licensed origins.

## Overall control of origin licensing by cyclin-dependent kinases

Cyclin-dependent kinases (CDKs), master regulators of the cell cycle, are activated during late G1, where they eventually induce cells to progress through S phase, G2 and then mitosis; CDK activity is then abolished during late mitosis. Significantly, the licensing system is only active during late mitosis and G1 when CDK activity is low (Fig 1). Experiments performed in the fission yeast *S. pombe* first showed that if CDK activity were temporarily inhibited in cells at the G2 phase of the cell cycle, they would re-replicate their DNA<sup>14,15</sup>. This suggests that re-loading of Mcm(2-7) occurs in these CDK-deficient G2 cells. Subsequent work in a range of different organisms has supported this model by showing that CDKs can strongly inhibit the licensing system<sup>16-21</sup>. However, high CDK levels do not displace Mcm2-7 already bound to origins<sup>11,12</sup>, thus allowing the normal S phase programme to occur in the presence of S-phase-inducing CDKs (Fig 1). It is possible that different CDKs may differ in their ability to inhibit origin licensing, and CDKs normally active in G1 to prepare cells for S phase may be less repressive (see below).

Sometimes cells undergo unusual cell cycles where the daughter cells acquire more DNA than their parents. This can occur as a consequence of developmental signals (such as in the increase in chromosome number seen during cardiac myocyte development), or as a consequence of some insult to the cell (such as chemically-induced polyploidy). It is useful to separate these unusual cell cycles into two distinct classes, shown schematically in Figure 2. The first class comprises endoreplication cell cycles (endocycles)<sup>22</sup>, where periods of alternating high and low CDK activity still occur. In endocycles, re-licensing of origins occurs when the CDK activity present in G2 or mitotic cells is abolished before cytokinesis has occurred. This G1 re-entry may occur from G2, metaphase or anaphase. The duplicated genomes are held in a single nucleus except in the case where nuclear division is completed and cytokinesis alone is suppressed, giving a binucleate cell. An example is the

endoreplication cycles occurring during *Drosophila* development, where transient interruption of CDK levels after DNA replication leads to cycles of Mcm2-7 reloading and near-complete re-replication of the DNA when CDK levels are restored<sup>23-25</sup>. Because endocycles drive complete S phases, the resultant cells should have DNA contents that are powers of 2 (2, 4, 8, 16 etc) larger than the DNA content in the starting cell. When mitotic CDK activation is abolished by mutation of the *cdc13* (cyclin B) gene in *S. pombe*, multiple complete rounds of replication are seen and the cellular DNA content approximates this power series<sup>15</sup>.

The second way that DNA content might increase is shown in the lower part of Figure 2. In this case, the cell re-licenses and re-initiates forks at one or more replication origins before S phase has been completed (*origin re-firing*). The S phase CDK levels do not drop, but re-licensing occurs because the licensing components (ORC, Cdc6, Cdt1 or Mcm2-7) cannot respond to the inhibitory CDK signal. Since the re-licensing and re-replication of one particular origin would not be co-ordinated with any other origin, the resultant cellular DNA content would not represent any simple multiple of the original DNA content. If certain origins are more prone to re-firing, there would be localised amplification of the DNA surrounding them (much as is shown in the bottom panel of Box 1). One of the best studied examples of this phenomenon in a physiological system occurs within ovarian follicle cells during *Drosophila* oogenesis, where certain genes are amplified to ensure sufficient production of chorion proteins that make up the eggshell. This occurs by the repeated initiation of replication origins close to the amplified genes in the presence of constant CDK levels<sup>22,26</sup>.

## CDK targets for preventing re-licensing of origins

Significant progress has recently been made in understanding the mechanisms by which CDKs inhibit replication licensing. Mounting evidence suggests that CDKs are likely to block licensing by a number of partially redundant mechanisms, which is perhaps not surprising given the importance of preventing over-replication of genomic DNA. Indeed, it appears that all four proteins known to be involved in origin licensing (ORC, Cdc6, Cdt1 and Mcm2-7) may each be independently downregulated as a consequence of CDK activity. The redundancy of CDK control over licensing is dramatically demonstrated in a recent paper by Nguyen et al<sup>5</sup>. When CDK inhibition of ORC, Cdc6 and Mcm2-7 was specifically abrogated in the yeast *Saccharomyces cerevisiae*, partial re-replication of the genome occurred. This strongly supports the idea that the role of CDKs in preventing re-replication of DNA is primarily mediated by preventing re-licensing of DNA. Abrogation of CDK regulation on individual pairs of these proteins (ORC+Cdc6, ORC+Mcm2-7 or Cdc6+Mcm2-7) failed to induce significant re-replication of DNA, thus demonstrating the redundancy of the CDK control mechanisms. Since re-replication was only partial when all three of these CDK controls were abolished<sup>5</sup>, there may be further pathways preventing re-replication that were still active in these cells. It is also consistent with re-replication being due to “origin re-firing” (Fig 2) rather than by CDK oscillation.

Precisely how do CDKs block origin licensing? As discussed in more detail below, each of the four origin proteins (ORC, Cdc6, Cdt1 and Mcm2-7) may be independently regulated by CDKs. Figure 3 summarises these different mechanisms. This is not a complete list, and further inhibitory pathways may well be discovered. One striking feature shown in Figure 3 is that although the four origin proteins are highly conserved throughout the eukaryotic kingdom, the way that they are regulated by CDKs differ significantly. The regulation of these four different proteins by CDKs will now be discussed in turn.

## CDK regulation of ORC

In *S. cerevisiae*, the Orc2 subunit of ORC is phosphorylated by CDKs in late G1, S phase, G2 and mitosis<sup>5</sup>. When these phosphorylation sites were genetically removed from the *ORC2* gene, cells could undergo partial re-replication under conditions where Cdc6 and Mcm2-7 regulation by CDKs had been abrogated. The phosphorylation of Orc2 during the later stages of the cell cycle appears to be highly conserved throughout eukaryotic evolution, and has also been reported in *S. pombe* and *Xenopus* (frog). Phosphorylation of the *S. pombe* Orc2 homologue (Orp2) by CDK has recently been shown to regulate activity of the ORC complex, as deletion of CDK phosphorylation sites enhances the re-replication seen when the *S. pombe* Cdc6 homologue (Cdc18) is over-expressed<sup>27</sup>. The situation in metazoans appears somewhat more complex. In *Xenopus*, exposure of chromatin to high CDK levels (such as occur during mitosis) can release ORC from chromatin<sup>11,12</sup>, and this appears to play a small but significant role in preventing origin re-licensing<sup>8</sup>. Although ORC appears to bind DNA with increased affinity in early G1 when CDK activity is low, binding then weakens, not due to increases in CDK activity, but as a consequence of origin licensing (“licensing-dependent origin inactivation”), a process which may help to prevent re-licensing of origins later in the cell cycle<sup>12</sup>. In mammalian cells there is also evidence that the Orc1 subunit of ORC can be released from DNA during S phase and mitosis, leaving Orc2 still bound<sup>28,29</sup>. This effect is likely to be due to the high CDK levels present at this stage.

## CDK regulation of Cdc6

In yeasts, Cdc6 abundance is tightly controlled during the cell division cycle. *CDC6* transcription peaks during late mitosis and G1<sup>30-32</sup>, with transcription being under the control of the CDK-dependent transcription factor SWI4/Cdc10<sup>31,33</sup>. Protein levels are also controlled by cell-cycle specific degradation, probably involving two or more different pathways<sup>34,35</sup>, but again controlled by CDK activity<sup>34-36</sup>. To abolish both regulatory mechanisms and to permit DNA re-replication in *S. cerevisiae*, Nguyen et al<sup>5</sup> therefore expressed from a constitutively active promoter a truncated form of Cdc6 that is resistant to cell-cycle specific degradation.

In vertebrate cells, the regulation of Cdc6 is less well understood. Cdc6 appears to be present throughout the vertebrate cell cycle. Although cell cycle-dependent degradation of Cdc6 protein is seen, significant amounts of chromatin-bound Cdc6 are observed during G1, S and G2 phases<sup>37,38</sup>. Much of the soluble Cdc6 protein, however, is translocated from the nucleus to the cytoplasm when CDKs are activated in late G1, thus preventing it from further interaction with replication origins<sup>39-41</sup>. One possible explanation for these apparently contradictory results is that the chromatin-bound form of Cdc6 seen in S and G2 is not competent to support origin licensing, but may play another role in cell cycle regulation.

## CDK regulation of Cdt1

First identified in *S. pombe* as a gene induced by the CDK-dependent transcription factor Cdc10, Cdt1 mRNA and protein levels peak in late mitosis and early G1<sup>42-44</sup>. In HeLa cells, levels of Cdt1 also peak during G1<sup>43,45</sup>. Since a Cdt1 homologue has not yet been identified in *S. cerevisiae*, it is possible that the reason why re-replication was only partial in *S. cerevisiae* cells containing unregulated ORC, Cdc6 and Mcm2-7 was due to Cdt1 activity being inhibited by CDKs<sup>5</sup>.

Vertebrate cells are also able to control Cdt1 activity through a specific inhibitor called geminin<sup>8,45,46</sup>; no geminin homologue has yet been identified in yeast. In metaphase-arrested *Xenopus* eggs, geminin inhibition of Cdt1 is the major pathway for prevention of

origin licensing<sup>8</sup>. The abundance of geminin, however, has been shown to be indirectly regulated by CDKs. Geminin is specifically degraded during late mitosis by the Anaphase Promoting Complex (APC/C) that is also responsible for degrading cyclins and which itself is regulated by CDKs<sup>46</sup>. In mammalian cells, geminin levels remain low throughout G1 (when the APC/C is active) and levels rise again during S and G2, when the APC/C becomes inactivated and CDK levels rise<sup>45,46</sup>. APC/C regulation has been suggested as a means by which the specialized endocycles of *Drosophila*, mentioned above, are controlled<sup>22</sup>.

### CDK regulation of Mcm2-7

In *S. cerevisiae*, Mcm2-7 are present in the nucleoplasm only during late mitosis and early G1. Soluble Mcm2-7 are excluded from nuclei at other stages of the cell cycle, though origin-bound Mcm2-7 is still seen in S phase nuclei<sup>47-49</sup>. The nuclear exclusion of Mcm2-7 is dependent on the presence of CDK activity. Exclusion can be mediated by the *S. cerevisiae* G1 cyclins (Clns) as well as the B-type cyclins (Clbs)<sup>48</sup>, though the B-type cyclins may be more effective<sup>49</sup>. This nuclear exclusion, which formed a major part of the original licensing factor model<sup>1</sup> is an effective way of preventing re-replication of DNA as it separates the licence (Mcm2-7) from its substrate (DNA). However, there is little evidence that Mcm2-7 activity is regulated by subcellular localisation in other organisms. Mcm2-7 has been reported to be constitutively nuclear in *S. pombe*, *Drosophila*, *Xenopus* and a range of mammalian cells. Indeed, there is little evidence that Mcm2-7 are negatively regulated late in the cell cycle of other organisms (e.g. ref. <sup>19</sup>). However, the possibility of undiscovered modes of Mcm2-7 regulation (such as controlling its assembly into an active hexamer<sup>6</sup>) is still open.

### Licensing and the definition of the proliferative state

Only a small proportion of the cells that make up a multicellular organism are likely to be actively engaged in the cell division cycle at any one time. Some non-proliferating cells will have permanently withdrawn from the cell cycle as a result of terminal differentiation or senescence. Others can be easily stimulated to divide again by appropriate environmental signals such as growth factors; these cells are said to be 'quiescent', or in the G0 phase of the cell cycle. Evidence from a range of different organisms and cell types suggest that both G0 and permanently arrested cells have lost Mcm2-7 proteins and are functionally unlicensed<sup>50-56</sup>. Not only is Mcm2-7 removed from DNA as cells pass into G0, but the unbound protein is also lost from the cells. A similar reduction in Cdc6 protein is seen in G0 and permanently arrested cells<sup>53,54,56-58</sup>. ORC levels, however, seem to remain high on progression into quiescence<sup>52,53</sup>. The persistence of ORC in non-proliferating cells is consistent with it having a function in these cells that is independent of DNA replication, such as transcriptional silencing<sup>59</sup>.

A recent study of Mcm2-7 proteins in a variety of human tissues by Stoeber et al<sup>56</sup> consolidates these results, and suggests that the removal of the replication licence is a common pathway by which proliferation is restrained. An example is shown in Fig 4, where a section of human colon has been immunostained for Mcm2. The terminally differentiated (non-proliferating) cells at the top of the crypt contain virtually no Mcm2. At the base of the crypts are the stem cells, which although having a high capacity for self-renewal, divide relatively infrequently. These stem cells contain intermediate levels of Mcm2, consistent with them being at different points through the G1 - G0 transition. Between the stem cells and the terminally differentiated cells are the transit amplifying cells which are actively proliferating. These proliferating cells stain the most strongly for Mcm2.



The correlation between entry into G<sub>0</sub> and terminal differentiation with loss of Mcm2-7 is shown schematically in Figure 5. During late mitosis and early G<sub>1</sub>, replication origins become licensed, and they stay licensed throughout the G<sub>1</sub> period. From G<sub>1</sub>, cells have the choice to either enter S phase or to withdraw from the cell cycle. Entry into S phase is driven by rising CDK activity, which leads to the initiation of DNA replication and subsequent removal of Mcm2-7. Withdrawal from the cell cycle is accompanied by the gradual loss of Mcm2-7 in the absence of CDK activity or DNA replication. On re-entry into the cell cycle from G<sub>0</sub>, origins are re-licensed and only then can CDK activity induce entry into S phase<sup>53</sup>. The licensing pathway that is followed during the G<sub>0</sub>/G<sub>1</sub> transition may well be regulated differently from the licensing pathway that occurs on exit from mitosis. In particular, many of the pre-RC genes involved in licensing appear to have binding sites for the E2F transcription factor which is active during late G<sub>1</sub> or on exit from G<sub>0</sub><sup>9,51,57,60-65</sup>. Full E2F activity is dependent on Cdk4/6-cyclin D and Cdk2-cyclin E, suggesting that at the levels necessary to activate E2F, these particular CDKs may not inhibit licensing (Fig 5).

Detection of Mcm2-7 is therefore a powerful way of assessing the proliferative potential of cells. Since there is currently no formal way of distinguishing G<sub>1</sub> from G<sub>0</sub> cells, we would like to propose that the description of cells being in G<sub>1</sub> should be limited only to cells with licensed origins. The G<sub>0</sub> state can then be defined as: a reversible withdrawal from the cell cycle characterised by unlicensed origins and the absence of CDK activity. We believe that this definition would be useful as it has clear functional significance in distinguishing G<sub>0</sub> or differentiated cells that are not proliferating from G<sub>1</sub> cells engaged in the cell division cycle. This distinction, between cells containing Mcm2-7 and cells lacking it, has potential as a diagnostic marker since cancers with a high proportion of proliferating cells (high growth fraction) should stain strongly for Mcm2-7<sup>54,56,66,67</sup>. This powerful new approach has already given promising results in the diagnosis of cervical<sup>54</sup>, urothelial<sup>66</sup> and bronchial cancers<sup>67</sup>.

In their survey of Mcm2-7 levels in different human tissues, Stoeber et al<sup>56</sup> reported that the glandular epithelial cells of the breast showed an interesting exception to the correlation between Mcm2-7 presence and active proliferation. In breast cells from non-pregnant and non-lactating women, a large percentage of glandular epithelial cells (47-65%) expressed Mcm2-7 while only a small percentage (~6%) showed signs of proliferation. During pregnancy, when these cells proliferate rapidly, almost of all them contained Mcm2-7, but expression plunged to <3% during lactation when the glandular epithelial cells undergo differentiation to the secretory state. The persistence of Mcm2-7 in non-proliferating breast may be an evolutionary relic from times when women spent most of their fertile years either pregnant or lactating, and when it was therefore unnecessary for these cells to be able to withdraw from the G<sub>1</sub> state. An important question raised by this finding is whether licensed but slowly proliferating cells such as these have a higher risk of undergoing malignant transformation. Since the lack of origin licensing may be an important mechanism restraining the proliferation of G<sub>0</sub> cells, it is possible that failure to down-regulate the licensing system (as in these breast cells) may make transition to uncontrolled proliferation significantly easier to achieve. These new observations may therefore have important implications for the pathogenesis of breast cancer, and urgently demand further study.

## Concluding Remarks

The results discussed in this review show that the replication licensing system not only plays a central role in ensuring precise chromosome duplication in each cell cycle, but it also plays an important role in down-regulating the proliferative capacity of cells when they withdraw from the cell cycle. This conclusion appears to have important practical implications for cancer diagnosis, which we expect will be consolidated by future work.

## Acknowledgments

Thanks to Inke N athke and Margret Michalski-Blow for comments on the manuscript. JJB is supported by Cancer Research Campaign [CRC] grant SP2385/0101. BJH is supported by a UBI studentship.

## Glossary

<b>CDK</b>	cyclin dependent kinase, consisting of a small kinase subunit complexed with an activating cyclin subunit. Key activator of cell cycle transitions.
<b>Licensing</b>	the loading of functional Mcm2-7 hexamers onto replication origins to enable them to support a single round of replication.
<b>Mcm2-7</b>	6 related <b>minichromosome maintenance</b> proteins (Mcm2, 3, 4, 5, 6 and 7) found in a hexameric complex.
<b>ORC</b>	the <b>origin recognition complex</b> , comprising 6 polypeptides: Orc1, 2, 3, 4, 5 and 6.
<b>pre-RC</b>	the <b>pre-replicative complex</b> of proteins bound to replication origins during G1 but not G2 of the cell cycle.
<b>Replication licensing system</b>	the set of proteins required to license replication origins.
<b>Replication origin</b>	a site on chromosomal DNA where a bi-directional pair of replication forks initiate.

## References


1. Blow JJ, Laskey RA. A role for the nuclear envelope in controlling DNA replication within the cell cycle. *Nature*. 1988; 332:546–548. [PubMed: 3357511]
2. Diffley JFX. Building the perfect switch. *Current Biol*. 2001; 11:R367–370.
3. Lei M, Tye BK. Initiating DNA synthesis: from recruiting to activating the MCM complex. *J. Cell Sci*. 2001; 114:1447–1454. [PubMed: 11282021]
4. Blow JJ. Control of chromosomal DNA replication in the early *Xenopus* embryo. *EMBO J*. 2001; 20:3293–3297. [PubMed: 11432816]
5. Nguyen VQ, et al. Cyclin-dependent kinases prevent DNA re-replication through multiple mechanisms. *Nature*. 2001; 411:1068–1073. [PubMed: 11429609]
6. Prokhorova TA, Blow JJ. Sequential MCM/P1 subcomplex assembly is required to form a heterohexamer with replication licensing activity. *J. Biol. Chem*. 2000; 275:2491–2498. [PubMed: 10644704]
7. Labib K, Diffley JF. Is the MCM2-7 complex the eukaryotic DNA replication fork helicase? *Curr. Opin. Genet. Dev*. 2001; 11:64–70.
8. Tada S, et al. Repression of origin assembly in metaphase depends on inhibition of RLF-B/Cdt1 by geminin. *Nat. Cell Biol*. 2001; 3:107–113. [PubMed: 11175741]
9. Whittaker AJ, et al. *Drosophila* Double parked: a conserved, essential replication protein that colocalizes with the origin recognition complex and links DNA replication with mitosis and the down-regulation of S phase transcripts. *Genes Dev*. 2000; 14:1765–1776. [PubMed: 10898791]
10. Donovan S, et al. Cdc6p-dependent loading of Mcm proteins onto pre-replicative chromatin in budding yeast. *Proc. Natl. Acad. Sci. U.S.A.* 1997; 94:5611–5616. [PubMed: 9159120]
11. Hua XH, Newport J. Identification of a preinitiation step in DNA replication that is independent of origin recognition complex and cdc6, but dependent on cdk2. *J. Cell Biol*. 1998; 140:271–281. [PubMed: 9442103]
12. Rowles A, et al. Changes in association of the *Xenopus* origin recognition complex with chromatin on licensing of replication origins. *J. Cell Sci*. 1999; 112:2011–2018. [PubMed: 10341218]

13. Maiorano D, et al. XCDT1 is required for the assembly of pre-replicative complexes in *Xenopus laevis*. *Nature*. 2000; 404:622–625. [PubMed: 10766247]
14. Broek D, et al. Involvement of p34cdc2 in establishing the dependency of S phase on mitosis. *Nature*. 1991; 349:388–393. [PubMed: 1992340]
15. Hayles J, et al. Temporal order of S phase and mitosis in fission yeast is determined by the state of the p34cdc2-mitotic B cyclin complex. *Cell*. 1994; 78:813–822. [PubMed: 8087848]
16. Dahmann C, et al. S-phase-promoting cyclin-dependent kinases prevent re-replication by inhibiting the transition of replication origins to a pre-replicative state. *Current Biol*. 1995; 5:1257–1269.
17. Hua XH, et al. A role for Cdk2 kinase in negatively regulating DNA replication during S phase of the cell cycle. *J. Cell Biol*. 1997; 137:183–192. [PubMed: 9105046]
18. Itzhaki JE, et al. Construction by gene targeting in human cells of a ‘conditional’ CDC2 mutant that rereplicates its DNA. *Nature Genet*. 1997; 15:258–265. [PubMed: 9054937]
19. Mahbubani HM, et al. Cell cycle regulation of the replication licensing system: involvement of a Cdk-dependent inhibitor. *J. Cell Biol*. 1997; 136:125–135. [PubMed: 9008708]
20. Bates S, et al. Cell cycle arrest and DNA endoreduplication following p21(Waf1/Cip1) expression. *Oncogene*. 1998; 17:1691–1703. [PubMed: 9796698]
21. Noton E, Diffley JFX. CDK inactivation is the only essential function of the APC/C and the mitotic exit network proteins for origin resetting during mitosis. *Mol. Cell*. 2000; 5:85–95. [PubMed: 10678171]
22. Edgar BA, Orr-Weaver TL. Endoreplication cell cycles: More for less. *Cell*. 2001; 105:297–306. [PubMed: 11348589]
23. Follette PJ, et al. Fluctuations in Cyclin E levels are required for multiple rounds of endocycle S phase in *Drosophila*. *Current Biol*. 1998; 8:235–238.
24. Su TT, O’Farrell PH. Chromosome association of minichromosome maintenance proteins in *Drosophila* endoreplication cycles. *J. Cell Biol*. 1998; 140:451–460. [PubMed: 9456309]
25. Weiss A, et al. Continuous Cyclin E expression inhibits progression through endoreduplication cycles in *Drosophila*. *Current Biol*. 1998; 8:239–242.
26. Calvi BR, et al. Cell cycle control of chorion gene amplification. *Genes Dev*. 1998; 12:734–744. [PubMed: 9499407]
27. Vas A, et al. Control of DNA rereplication via Cdc2 phosphorylation sites in the origin recognition complex. *Mol. Cell. Biol*. 2001; 21:5767–5777. [PubMed: 11486016]
28. Natale DA, et al. Selective instability of Orc1 protein accounts for the absence of functional origin recognition complexes during the M-G(1) transition in mammals. *EMBO J*. 2000; 19:2728–2738. [PubMed: 10835370]
29. Kreitz S, et al. The human origin recognition complex protein 1 dissociates from chromatin during S phase in HeLa cells. *J. Biol. Chem*. 2001; 276:6337–6342. [PubMed: 11102449]
30. Zwerschke W, et al. The *Saccharomyces cerevisiae* Cdc6 gene is transcribed at late mitosis and encodes a ATP/GTPase controlling S-phase initiation. *J. Biol. Chem*. 1994; 269:23351–23356. [PubMed: 8083240]
31. McNerny CJ, et al. A novel Mcm1-dependent element in the SWI4, CLN3, CDC6, and CDC47 promoters activates M/G(1)-specific transcription. *Genes Dev*. 1997; 11:1277–1288. [PubMed: 9171372]
32. Baum B, et al. Cdc18 transcription and proteolysis couple S phase to passage through mitosis. *EMBO J*. 1998; 17:5689–5698. [PubMed: 9755169]
33. Kelly TJ, et al. The fission yeast Cdc18+ gene-product couples S-phase to Start and mitosis. *Cell*. 1993; 74:371–382. [PubMed: 7916658]
34. Elsasser S, et al. Phosphorylation controls timing of Cdc6p destruction: A biochemical analysis. *Mol. Biol. Cell*. 1999; 10:3263–3277. [PubMed: 10512865]
35. Drury LS, et al. The cyclin-dependent kinase Cdc28p regulates distinct modes of Cdc6p proteolysis during the budding yeast cell cycle. *Current Biol*. 2000; 10:231–240.
36. Jallepalli PV, et al. Regulation of the replication initiator protein p65(cdc18) by CDK phosphorylation. *Genes Dev*. 1997; 11:2767–2779. [PubMed: 9353247]




37. Coverley D, et al. Chromatin-bound Cdc6 persists in S and G(2) phases in human cells, while soluble Cdc6 is destroyed in a cyclin A-cdk2 dependent process. *J. Cell Sci.* 2000; 113:1929–1938. [PubMed: 10806104]
38. Mendez J, Stillman B. Chromatin association of human origin recognition complex, Cdc6, and minichromosome maintenance proteins during the cell cycle: Assembly of prereplication complexes in late mitosis. *Mol. Cell. Biol.* 2000; 20:8602–8612. [PubMed: 11046155]
39. Saha P, et al. Human CDC6/Cdc18 associates with Orc1 and cyclin-cdk and is selectively eliminated from the nucleus at the onset of S phase. *Mol. Cell. Biol.* 1998; 18:2758–2767. [PubMed: 9566895]
40. Petersen BO, et al. Phosphorylation of mammalian CDC6 by Cyclin A/CDK2 regulates its subcellular localization. *EMBO J.* 1999; 18:396–410. [PubMed: 9889196]
41. Delmolino LM, et al. Multiple mechanisms regulate subcellular localization of human CDC6. *J. Biol. Chem.* 2001; 276:26947–26954. [PubMed: 11346650]
42. Hofmann JF, Beach D. cdt1 is an essential target of the Cdc10/Sct1 transcription factor: requirement for DNA replication and inhibition of mitosis. *EMBO J.* 1994; 13:425–434. [PubMed: 8313888]
43. Nishitani H, et al. The Cdt1 protein is required to license DNA for replication in fission yeast. *Nature.* 2000; 404:625–628. [PubMed: 10766248]
44. Yanow SK, et al. Expression of Cdc18/Cdc6 and Cdt1 during G2 phase induces initiation of DNA replication. *EMBO J.* 2001; 20:4648–4656. [PubMed: 11532929]
45. Wohlschlegel JA, et al. Inhibition of eukaryotic replication by geminin binding to Cdt1. *Science.* 2000; 290:2309–2312. [PubMed: 11125146]
46. McGarry TJ, Kirschner MW. Geminin, an inhibitor of DNA replication, is degraded during mitosis. *Cell.* 1998; 93:1043–1053. [PubMed: 9635433]
47. Hennessy KM, et al. Subcellular localization of yeast CDC46 varies with the cell cycle. *Genes Dev.* 1990; 4:2252–2263. [PubMed: 2279699]
48. Labib K, et al. G1-phase and B-type cyclins exclude the DNA-replication factor Mcm4 from the nucleus. *Nat. Cell Biol.* 1999; 1:415–422. [PubMed: 10559985]
49. Nguyen VQ, et al. Clb/Cdc28 kinases promote nuclear export of the replication initiator proteins Mcm2-7. *Current Biol.* 2000; 10:195–205.
50. Su TT, O'Farrell PH. Chromosome association of minichromosome maintenance proteins in *Drosophila* mitotic cycles. *J Cell Biol.* 1997; 139:13–21. [PubMed: 9314525]
51. Tsuruga H, et al. Expression, nuclear localization and interactions of human MCM/P1 proteins. *Biochem. Biophys. Res. Commun.* 1997; 236:118–125. [PubMed: 9223437]
52. Musahl C, et al. Stability of the replicative Mcm3 protein in proliferating and differentiating human cells. *Exp. Cell Res.* 1998; 241:260–264. [PubMed: 9633535]
53. Stoeber K, et al. Cdc6 protein causes premature entry into S phase in a mammalian cell-free system. *EMBO J.* 1998; 17:7219–7229. [PubMed: 9857179]
54. Williams GH, et al. Improved cervical smear assessment using antibodies against proteins that regulate DNA replication. *Proc. Natl. Acad. Sci. U.S.A.* 1998; 95:14932–14937. [PubMed: 9843993]
55. Sun W, et al. The replication capacity of intact mammalian nuclei in *Xenopus* egg extracts declines with quiescence, but the residual DNA synthesis is independent of *Xenopus* MCM proteins. *J. Cell Sci.* 2000; 113:683–695. [PubMed: 10652261]
56. Stoeber K, et al. DNA replication licensing and human cell proliferation. *J. Cell Sci.* 2001; 114:2027–2041. [PubMed: 11493639]
57. Yan Z, et al. Cdc6 is regulated by E2F and is essential for DNA replication in mammalian cells. *Proc. Natl. Acad. Sci. U.S.A.* 1998; 95:3603–3608. [PubMed: 9520412]
58. Williams RS, et al. A human protein related to yeast Cdc6p. *Proc. Natl. Acad. Sci. U.S.A.* 1997; 94:142–147. [PubMed: 8990175]
59. Fox CA, et al. The origin recognition complex has essential functions in transcriptional silencing and chromosomal replication. *Genes Dev.* 1995; 9:911–924. [PubMed: 7774809]

60. Asano M, Wharton RP. E2F mediates developmental and cell cycle regulation of ORC1 in *Drosophila*. *EMBO J.* 1999; 18:2435–2448. [PubMed: 10228158]
61. Leone G, et al. E2F3 activity is regulated during the cell cycle and is required for the induction of S phase. *Genes Dev.* 1998; 12:2120–2130. [PubMed: 9679057]
62. Ohtani K, et al. Regulation of cell growth-dependent expression of mammalian CDC6 gene by the cell cycle transcription factor E2F. *Oncogene.* 1998; 17:1777–1785. [PubMed: 9778043]
63. Ohtani K, et al. Cell growth-regulated expression of mammalian MCM5 and MCM6 genes mediated by the transcription factor E2F. *Oncogene.* 1999; 18:2299–2309. [PubMed: 10327050]
64. Suzuki S, et al. Cloning and characterization of human MCM7 promoter. *Gene.* 1998; 216:85–91. [PubMed: 9714754]
65. Tsuruga H, et al. HsMCM6: A new member of the human MCM/P1 family encodes a protein homologous to fission yeast Mis5. *Genes Cells.* 1997; 2:381–399. [PubMed: 9286856]
66. Stoeber K, et al. Immunoassay for urothelial cancers that detects DNA replication protein Mcm5 in urine. *Lancet.* 1999; 354:1524–1525. [PubMed: 10551502]
67. Tan D-F, et al. MCM2 - a promising marker for premalignant lesions of the lung: a cohort study. *BioMed Central Cancer.* 2001; 1:6. [PubMed: 11472637]

**Box 1**

Ensuring precise chromosome replication. A small segment of chromosomal DNA, replicated from 3 origins is shown during the cell cycle. Middle panel: successful duplication. Top panel: under-replication due to the failure of one of the origins to fire. As sister chromatids are separated during anaphase, the chromosome is likely to be broken near the unreplicated section. Bottom panel: over-replication, due to one of the origins firing a second time in S phase. The local duplication of DNA in the vicinity of the over-firing origin is likely to represent an irreversible genetic change, and might be resolved to form a tandem duplication.


— unreplicated DNA; — replicated DNA; — re-replicated DNA The four stages of the cell cycle - G1, S (DNA synthesis), G2 and M (mitosis) - are shown below.



**Figure 1.**

Replication licensing and CDK activity through the cell cycle.

A small segment of chromosomal DNA is depicted at different cell cycle stages, with bound (red hexagons, M) or unbound (blue hexagons, M) Mcm2-7. The activity of the replication licensing system (RLS, purple) and cyclin-dependent kinases (CDK, green) at the different stages are shown in the central circle. Inset, the sequence of events occurring as each origin binds Mcm2-7 and becomes licensed. The loading of ORC (purple), Cdt1 (yellow) and Cdc6 (green), and then Mcm2-7 (red, M) is shown. At some time after licensing is complete, ORC, Cdc6 and Cdt1 may become inactivated, as indicated by grey shading.



**Figure 2.**


Different routes by which cellular DNA content may increase.

A small segment of chromosomal DNA is depicted at different cell cycle stages. Red hexagons show Mcm2-7 bound to origins in G1 and S. Outer ring (black arrows): the normal sequence of cell cycle events. Red arrows show routes by which cellular DNA content is increased (endocycles and origin re-firing). CDK activity in S, G2 and M is denoted by green colouring.




CDKs			
ORC	Cdc6	Cdt1	Mcm2-7
<p><i>S. cerevisiae</i> Inhibition by CDK-dependent Orc2 phosphorylation.</p> <p><i>Humans</i> <i>Xenopus</i> CDK-dependent complex disassembly or removal from chromatin?</p>	<p><i>S. cerevisiae</i> <i>S. pombe</i> CDK-dependent proteolysis.</p> <p>CDK-regulated transcription.</p> <p><i>Humans</i> <i>Xenopus</i> CDK-dependent nuclear export of soluble protein (though chromatin bound protein persists).</p> <p>CDK-dependent proteolysis?</p>	<p><i>S. pombe</i> CDK-dependent proteolysis.</p> <p>CDK-regulated transcription.</p> <p><i>Humans</i> <i>Xenopus</i> Inhibition by geminin (regulated by CDK-dependent proteolysis).</p> <p>CDK-dependent proteolysis?</p> <p>Cell-cycle dependent</p>	<p><i>S. cerevisiae</i> CDK-dependent nuclear exclusion.</p> <p><i>Humans</i> <i>Xenopus</i> No clear evidence for CDK regulation.</p>

**Figure 3.**  
Pathways for CDK inhibition of origin licensing.  
The ways that CDKs inhibit the activity of ORC, Cdc6, Cdt1 and Mcm2-7 in *S. cerevisiae*, *S. pombe*, *Xenopus* and humans.



**Figure 4.** Mcm2 protein expression in differentiating colonic epithelial cells. Indirect immunoperoxidase staining of colon with an anti-Mcm2 antibody. Anatomical regions containing stem cells, rapidly proliferating cells and terminally differentiated cells are indicated. Reproduced from ref. <sup>56</sup> with permission.



**Figure 5.**

Entry and exit of cycling cells into quiescence and terminal differentiation.

On the left is a cartoon of cells passing through four phases of the cell division cycle. The presence of licensed origins is shown in red, and the presence of active CDKs is shown in green. When cells pass from G1 into G0 or terminal differentiation, origins become unlicensed. When G0 cells are stimulated to re-enter G1 their origins become re-licensed. It is currently unclear whether CDK reactivation of the E2F transcription system is required for this re-licensing to occur.